{"symbol":"BSX","fiscalQuarter":"Q2-2026","reportDate":"2010-02-10","reportTime":"AMC","status":"upcoming","company":{"name":"Boston Scientific Corporation","sector":"Health Care","industry":"Health Care Equipment"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BSX/earnings/Q2-2026","preBrief":{"companySnapshot":"Boston Scientific Corporation (BSX) is a leading medical device company that develops and manufactures a wide range of products used in various medical fields, including cardiology, urology, and endoscopy. With a market cap of $77 billion, the company plays a crucial role in the healthcare sector, focusing on improving patient outcomes through innovative technology.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of the company's profitability and financial health, which investors closely watch.","consensus":"N/A"},{"name":"Revenue Growth","why":"Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term success.","consensus":"N/A"}],"lastQuarterRecap":{"summary":"In Q1-2026, Boston Scientific reported an EPS of $0.80, matching analyst expectations and resulting in a positive stock reaction of nearly 9% the following day. The company has consistently beaten EPS estimates in recent quarters, showcasing strong operational performance.","promises":[]},"wallStreetExpectations":{"summary":"Overall expectations for Boston Scientific's upcoming earnings are mixed, given the lack of analyst estimates and management guidance. Investors are keen to see if the company can continue its trend of beating EPS expectations.","bullCase":"The optimistic view hinges on Boston Scientific continuing its strong performance, potentially reporting higher-than-expected EPS and revenue growth, which could drive the stock higher.","bearCase":"On the flip side, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the recent volatility."},"optionsSignal":{"impliedMove":"1.36%","context":"The options market is pricing in a modest move of about 1.36%, suggesting that traders expect limited volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+0.63%","reaction":"+8.99%"},{"quarter":"Q4-2025","epsSurprise":"+2.96%","reaction":"-17.59%"},{"quarter":"Q3-2025","epsSurprise":"+5.63%","reaction":"+3.95%"},{"quarter":"Q2-2025","epsSurprise":"+3.73%","reaction":"+4.46%"},{"quarter":"Q1-2025","epsSurprise":"+12.28%","reaction":"+4.07%"}],"pivotalQuestions":[{"question":"What will the EPS be for Q2-2026?","whyItMatters":"Given the company's history of beating EPS estimates, this number will be crucial for investor sentiment and stock performance."},{"question":"How is revenue growth trending in key segments?","whyItMatters":"Understanding revenue growth in critical areas will help gauge the company's market position and future prospects."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $0.85 or higher would confirm the bull case, indicating strong operational performance.","bearTrigger":"An EPS below $0.75 would signal potential issues, confirming the bear case.","context":"This quarter's performance will be closely scrutinized, especially given the company's strong track record of beating EPS estimates."},"scenarioPlaybook":{"beatAndRaise":"If Boston Scientific beats expectations, history suggests the stock could rise by an average of 0.45% in the following day, confirming the company's strong momentum.","inLineCautious":"If results are in line with expectations, the stock may see a muted reaction, reflecting cautious investor sentiment.","miss":"In the event of a miss, the stock could decline significantly, as seen in past reactions where misses led to notable drops."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating Boston Scientific's ability to continue its streak of EPS beats, especially given its recent operational improvements.","supportingPoints":["The company has consistently surprised on the upside with a 100% EPS beat rate over the last eight quarters.","The options market is pricing a lower move than historical averages, suggesting potential for greater volatility.","Recent performance trends indicate strong demand in key segments, which may not be fully reflected in current estimates."],"riskToConsensus":"If the EPS comes in below $0.75, it could challenge the current positive sentiment surrounding the stock."},"whatToListenFor":["Any updates on new product launches or innovations in their medical devices.","Insights into market demand trends in key segments like cardiology and urology.","Management's outlook on future revenue growth and market expansion.","Details on cost management and operational efficiencies.","Any commentary on competitive pressures in the healthcare equipment industry."],"metaDescription":"Boston Scientific (BSX) reports Q2 2026 earnings on February 10. Investors are watching for EPS and revenue growth trends."}}